Recursion Pharmaceuticals (RXRX) has been drawing attention after recent trading, with the stock closing at $4.67. Investors are weighing this price against the company’s clinical pipeline and ongoing ...

Elon Musk says social platform X will open-source a new recommendation algorithm within seven days, exposing all code behind organic and ad post suggestions and updating it every four weeks with ...

TL;DR: Elon Musk says the algorithm that determines what appears in each user's X feed will be made public within a week – a move he claims will bring transparency to the platform's inner workings.

He open-sourced Twitter’s algorithm back in 2023, but then never updated the GitHub. He open-sourced Twitter’s algorithm back in 2023, but then never updated the GitHub. is the Verge’s weekend editor.

We recently published 10 Stocks With Massive Gains; 5 at Record Highs. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was one of the top performers on Wednesday. Recursion extended its winning streak ...

Google launched four official and confirmed algorithmic updates in 2025, three core updates and one spam update. This is in comparison to last year, in 2024, where we had seven confirmed updates, then ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

TikTok’s algorithm favors mental health content over many other topics, including politics, cats and Taylor Swift, according to a Washington Post analysis. At first, the mental health-related videos ...

For the first time, Instagram will start letting you control the topics its algorithm recommends, much as you now can on TikTok. The new feature is starting with the Reels tab but will eventually come ...

Monday - Friday, 6:00 - 7:00 PM ET It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...